Search

Author/Creator Jugl, Steffen

1. 169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. (25th April 2018)

Authors:
Chinoy, Hector; Gossec, Laure; Kvien, Tore K; Conaghan, Philip G; Østergaard, Mikkel; Gladman, Dafna; Mease, Philip; Rasouliyan, Lawrence; Pricop, Luminita; Gaillez, Corine; Jugl, Steffen
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 173 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data. (25th April 2018)

Authors:
Tahir, Hasan; Maksymowych, Walter; Choy, Ernest; Yazici, Yusuf; Walsh, Jessica; Thom, Howard; Kalyvas, Chrysostomos; Fox, Todd; Gandi, Kunal; Jugl, Steffen
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 175 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data. (25th April 2018)

Authors:
Kaul, Arvind; Strand, Vibeke; McInnes, Iain; Mease, Philip; Choy, Ernest; Nash, Peter; Thom, Howard; Kalyvas, Chrysostomos; Gandhi, Kunal; Pricop, Luminita; Jugl, Steffen
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 176 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. (25th April 2018)

Authors:
Marzo-Ortega, Helena; Kvien, Tore K; Deodhar, Atul A; Gossec, Laure; Conaghan, Philip G; Strand, Vibeke; Østergaard, Mikkel; Williams, Nicole; Porter, Brian; Gandi, Kunal; Jugl, Steffen
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 184 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study. (25th April 2018)

Authors:
McInnes, Iain; Smolen, Josef S; Kvien, Tore K; Pricop, Luminita; Fox, Todd; Rasouliyan, Lawrence; Jugl, Steffen; Gaillez, Corine
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. (26th February 2019)

Authors:
Strand, Vibeke; McInnes, Iain; Mease, Philip; Nash, Peter; Thom, Howard; Kalyvas, Chrysostomos; Hunger, Matthias; Gandhi, Kunal; Pricop, Luminita; Jugl, Steffen; Choy, Ernest
Journal:
Journal of comparative effectiveness research
Issue:
Volume 8:Number 7(2019)
Page Start:
497
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗